Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Eich ML, Rodriguez Pena MDC, Chandrashekar DS, Chaux A, Agarwal S, Gordetsky JB, Ferguson JE, Sonpavde GP, Netto GJ, Varambally S.

Transl Oncol. 2019 Aug 7;12(11):1416-1424. doi: 10.1016/j.tranon.2019.07.012. [Epub ahead of print]

2.

Mitochondrial C1-tetrahydrofolate synthase (MTHFD1L) supports the flow of mitochondrial one-carbon units into the methyl cycle in embryos.

Pike ST, Rajendra R, Artzt K, Appling DR.

J Biol Chem. 2010 Feb 12;285(7):4612-20. doi: 10.1074/jbc.M109.079855. Epub 2009 Nov 30.

3.

Deletion of the neural tube defect-associated gene Mthfd1l disrupts one-carbon and central energy metabolism in mouse embryos.

Bryant JD, Sweeney SR, Sentandreu E, Shin M, Ipas H, Xhemalce B, Momb J, Tiziani S, Appling DR.

J Biol Chem. 2018 Apr 20;293(16):5821-5833. doi: 10.1074/jbc.RA118.002180. Epub 2018 Feb 26.

4.

MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer.

Agarwal S, Behring M, Hale K, Al Diffalha S, Wang K, Manne U, Varambally S.

Transl Oncol. 2019 Aug 14;12(11):1461-1467. doi: 10.1016/j.tranon.2019.07.011. [Epub ahead of print]

5.

The role of mitochondrial folate enzyme MTHFD1L in esophageal squamous cell carcinoma.

Yang YS, Yuan Y, Hu WP, Shang QX, Chen LQ.

Scand J Gastroenterol. 2018 May;53(5):533-540. doi: 10.1080/00365521.2017.1407440. Epub 2017 Nov 24.

PMID:
29171320
6.

Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma.

Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, Law CT, Tsang FH, Wei LL, Chan CY, Wong CM, Ng IO, Wong CC.

J Clin Invest. 2017 May 1;127(5):1856-1872. doi: 10.1172/JCI90253. Epub 2017 Apr 10.

7.

Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in mice.

Momb J, Lewandowski JP, Bryant JD, Fitch R, Surman DR, Vokes SA, Appling DR.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):549-54. doi: 10.1073/pnas.1211199110. Epub 2012 Dec 24.

8.

Formate supplementation enhances folate-dependent nucleotide biosynthesis and prevents spina bifida in a mouse model of folic acid-resistant neural tube defects.

Sudiwala S, De Castro SC, Leung KY, Brosnan JT, Brosnan ME, Mills K, Copp AJ, Greene ND.

Biochimie. 2016 Jul;126:63-70. doi: 10.1016/j.biochi.2016.02.010. Epub 2016 Feb 23.

9.

Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression.

Eszlari N, Kovacs D, Petschner P, Pap D, Gonda X, Elliott R, Anderson IM, Deakin JF, Bagdy G, Juhasz G.

Transl Psychiatry. 2016 Mar 1;6:e745. doi: 10.1038/tp.2016.19.

10.

Alcohol Dehydrogenase 5 Is a Source of Formate for De Novo Purine Biosynthesis in HepG2 Cells.

Bae S, Chon J, Field MS, Stover PJ.

J Nutr. 2017 Apr;147(4):499-505. doi: 10.3945/jn.116.244467. Epub 2017 Feb 22.

11.

Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase.

Anguera MC, Field MS, Perry C, Ghandour H, Chiang EP, Selhub J, Shane B, Stover PJ.

J Biol Chem. 2006 Jul 7;281(27):18335-42. Epub 2006 Apr 20.

12.

Mitochondrial methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetases.

Christensen KE, Mackenzie RE.

Vitam Horm. 2008;79:393-410. doi: 10.1016/S0083-6729(08)00414-7. Review.

PMID:
18804703
13.

Nuclear enrichment of folate cofactors and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) protect de novo thymidylate biosynthesis during folate deficiency.

Field MS, Kamynina E, Agunloye OC, Liebenthal RP, Lamarre SG, Brosnan ME, Brosnan JT, Stover PJ.

J Biol Chem. 2014 Oct 24;289(43):29642-50. doi: 10.1074/jbc.M114.599589. Epub 2014 Sep 11.

14.

Deletion of neural tube defect-associated gene Mthfd1l causes reduced cranial mesenchyme density.

Shin M, Vaughn A, Momb J, Appling DR.

Birth Defects Res. 2019 Sep 13. doi: 10.1002/bdr2.1591. [Epub ahead of print]

PMID:
31518072
15.

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM.

Cancer Res. 1997 Mar 15;57(6):1116-23.

17.

Folate metabolic pathways in Leishmania.

Vickers TJ, Beverley SM.

Essays Biochem. 2011;51:63-80. doi: 10.1042/bse0510063. Review.

18.

The folate cycle is a new metabolic weakness of cancer.

Lee D, Wong CC.

Mol Cell Oncol. 2017 May 19;4(6):e1327004. doi: 10.1080/23723556.2017.1327004. eCollection 2017.

19.

An NTD-associated polymorphism in the 3' UTR of MTHFD1L can affect disease risk by altering miRNA binding.

Minguzzi S, Selcuklu SD, Spillane C, Parle-McDermott A.

Hum Mutat. 2014 Jan;35(1):96-104. doi: 10.1002/humu.22459.

PMID:
24123340
20.

Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis.

Field MS, Kamynina E, Watkins D, Rosenblatt DS, Stover PJ.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):400-5. doi: 10.1073/pnas.1414555112. Epub 2014 Dec 29.

Supplemental Content

Support Center